MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
Syncromune*
Organization & Developments: Syncromune
Parents
Syncromune*
Children
*Enables personalized autologous vaccines for cancer antigens.
*Immunotherapy utilizes intratumoral technology to synchronize the timing and location of tumor antigen release with the functional activation of immune cells
*Intratumoral immunotherapy to treat metastatic solid tumor cancers.
2024: FDA awards fast track designation to SYNC-T SV-102 in mCRPC
2024: FDA grants Fast Track designation to Syncromune Inc. for drug-device combo for solid tumors in mCRPC_20240705_8a
Jumps
Finance & Acquisition: Syncromune
Key People: Syncromune